A MAJOR UPHEAVAL
This week (April 27–May 2, 2026) features a handful of US IPOs ranging from tiny micro-caps to a blockbuster asset-management debut. If you haven't noticed, things are heating up on the IPO market.
Here's a technical rundown of each one, with the key deal details, underwriters, and what the companies actually do.
|
Raise
~$15M
|
Shares / Price
3M @ $5.00 Fixed
|
Underwriter
Oak Ridge Financial
|
Founded
2017
|
A small but fascinating structural heart device play. Encore develops, manufactures, and sells tiny implantable septal occlusion devices delivered via catheter — no open-heart surgery needed. These fix defects like patent foramen ovale (PFO) that can cause strokes or migraines in adults and kids.
The tech already has CE Mark approval and has been implanted in over 35,000 patients outside the US. They're using the IPO to fund US clinical trials and FDA approval.
|
Raise
$17.1M
|
Shares / Price
2.625M @ $6–$7
|
Underwriter
Eddid Securities USA
|
Revenue
~$22M (recent)
|
Houston-based EPC firm that builds and integrates complex industrial facilities. They specialize in critical process systems for energy, electronics/semiconductors, automotive, renewable energy, and advanced manufacturing — often helping international companies set up US operations.
Revenue can be lumpy because it's project-based, but they're expanding into proprietary modular water treatment systems for quick-deploy clean water.
|
Raise
$25M
|
Shares / Price
5M @ $4–$6
|
Underwriter
Eddid Securities USA
|
Revenue
~$16M (recent)
|
Toronto-based operator/franchisor running Japanese-style restaurants in Canada (Ajisen Ramen — 4 company-owned, 9 franchised in Ontario) and Hong Kong (7 locations: Yakiniku Kakura, Yakiniku 802, and Ufufu Cafe). They also supply ingredients and management services to franchisees.
|
Raise
$50M
|
Shares / Price
4.35M @ $10–$13
|
Syndicate
Cantor, Roth, Research Capital+
|
Land
~3,347 acres, Montana
|
Pure exploration-stage mining story with big Montana roots. The Canadian-domiciled company holds mineral claims in the historic Butte district, targeting silver, zinc, gold, lead, and copper — especially at its flagship Rainbow Block property with tons of historical data and existing infrastructure.
No revenue yet — classic pre-production explorer. IPO proceeds will fund drilling toward a feasibility study.
|
Raise
~$5B
|
Shares / Price
100M @ $50 Fixed
|
Underwriters
Citi, UBS, BofA, Jefferies, Wells
|
AUM
~$30–31B
|
The headline-grabber: Bill Ackman's alternative asset management firm going public in a massive combined offering alongside a new closed-end fund (PSUS). The management company runs the strategy — concentrated, long-term bets on large-cap companies, modeled a bit after Buffett-style permanent capital vehicles.
The IPO gives retail investors indirect exposure to Ackman's platform while the fund side democratizes access.
|
Raise
$201M
|
Shares / Price
11.8M @ $16–$18
|
Lead Underwriters
MS, Jefferies, Evercore, Guggenheim
|
Stage
Phase 2 → Phase 3
|
Clinical-stage company developing inhaled versions of two proven oral drugs — pirfenidone (AP01) and nintedanib (AP02) — for idiopathic pulmonary fibrosis (IPF) and other progressive lung scarring diseases. Delivering medicine straight to the lungs aims to boost efficacy while slashing systemic side effects.
Lead programs are in Phase 2, with Phase 3 funded by this IPO. Backed by Novo Holdings and other big-name investors.
It's a mixed bag this week — tiny industrials and restaurants alongside a marquee name and a couple of resource/biotech bets. Something for every risk appetite.
As always with IPOs, do your own homework on the S-1s, and good luck if you're eyeing any of these. Markets can shift fast.
Look out for a full breakdown and the % gains we expect on each of these deals.
"Thank you all and have a great week."
Tim
IPO Stream
